Description
RAD-140 (Testolone, Vosilasarm) is a non-steroidal, oral selective androgen receptor modulator with exceptionally high binding affinity to the androgen receptor. Ki values are reported in the Miller studies at 7 nM - compared to 29 nM for testosterone and 10 nM for DHT.
In the classic levator ani assay RAD-140 shows an anabolic-to-androgenic ratio of over 90:1, making it one of the most selective SARMs ever characterized. In preclinical studies on gonadectomized rats RAD-140 demonstrates muscle-building effects without the prostate stimulus seen with classical steroids.
An important property is neuroprotection: in a 2014 study (Endocrinology) RAD-140 showed neuroprotective effects via the AR pathway in cultured neurons and kainate-lesioned male rats. This property has made RAD-140 a research candidate in Alzheimer’s and neurodegeneration studies.
Pharmacokinetically RAD-140 is orally bioavailable with a half-life of about 60 hours - substantially longer than most other SARMs. Practically this means once-daily dosing, with steady-state reached after 1-2 weeks. Like all AR agonists, RAD-140 suppresses the HPG axis.
Vosilasarm (the brand name under which RAD-140 is being developed by Ellipses Pharma as a breast cancer therapeutic) is currently in clinical trials.
You can order RAD-140 as oral tablets in one bottle with 10mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
RAD-140 sits in the mid range of the risk scale. The high binding affinity makes the compound potent, and its suppression and lipid effects are correspondingly pronounced in the documentation.
Documented in studies and the literature:
- HPG suppression: like all AR agonists, RAD-140 suppresses the HPG axis - due to the long half-life the suppression is measurable for weeks after discontinuation.
- HDL suppression: a lowering of HDL cholesterol is documented as a class effect of SARMs.
- Liver markers: an elevation of liver enzymes is notably described under RAD-140 in the literature.
- PCT requirement: because of the pronounced and long-lingering HPG suppression, a SERM PCT after the cycle is customary in the literature.
Monitoring via bloodwork is recommended. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140 - ACS Medicinal Chemistry Letters 2011, Miller et al: First complete preclinical characterization including binding affinity and anabolic profile.
- Selective Androgen Receptor Modulator RAD140 Is Neuroprotective in Cultured Neurons and Kainate-Lesioned Male Rats - Endocrinology 2014, Jayaraman et al: Neuroprotective effects via the AR pathway in neurons and a rat model.
- Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action - Clinical Cancer Research 2017, Yu et al: Antitumor activity in AR/ER-positive breast cancer models, basis for clinical development.
- Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications - Sexual Medicine Reviews 2019, Solomon et al: Review of the SARM class, situating RAD-140 in the research context.
- Preclinical assessment of the selective androgen receptor modulator RAD140 to increase muscle mass and bone mineral density - Physiological Reports 2025, Puskas et al: Recent preclinical assessment of RAD-140 on muscle mass and bone mineral density.
